Every 8-K that NuSkin Enterprises, Inc. (NUS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow NUS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NUS filings page.
Nu Skin Enterprises, Inc. (NUS) reported that Justin Keisel, its Executive Vice President and President of Global Sales, began a medical leave of absence effective August 17, 2026. During his absence, Executive Vice President, Chief Operating Officer and Chief Legal Officer Chayce Clark will lead Mr. Keisel’s organization.
The company expresses support for Mr. Keisel as he focuses on his health. No changes to other executive roles or broader strategic initiatives are described in this report.
Nu Skin Enterprises reported weak second-quarter 2026 results heavily affected by non-cash charges. Revenue was $320.1 million, down 17.1% from $386.1 million, with a 1.0% FX headwind. Customers declined 14% to 660,037, Paid Affiliates fell 8%, and Sales Leaders decreased 9%, indicating broad-based volume pressure across regions.
GAAP diluted EPS was a loss of $(5.14), driven largely by a $78.9 million impairment charge and a substantial valuation allowance on deferred tax assets, producing an effective tax rate of (295.4)%. On a non-GAAP basis, EPS was $0.20, versus $0.43 a year earlier, and operating margin was 6.1% excluding impairment, compared with 8.0%.
For full-year 2026, the company now guides revenue to $1.28–$1.35 billion, a 14%–9% decline, and GAAP EPS of $(4.90)–$(4.73), or $0.70–$0.90 on an adjusted basis. Q3 2026 revenue is expected at $310–$340 million with adjusted EPS of $0.10–$0.20, while management continues rolling out the Prysm iO platform and preparing for an India launch.
Nu Skin Enterprises, Inc. reported results from its 2026 Annual Meeting of Stockholders. Stockholders approved and adopted the Amended and Restated 2024 Omnibus Incentive Plan, which had previously been approved by the board and its Compensation and Human Capital Committee, subject to stockholder approval.
All nine director nominees, including Emma S. Battle and Ryan S. Napierski, were elected with over 33.5 million votes each in favor and 5,430,258 broker non-votes recorded for each seat. Stockholders gave advisory approval of the Company’s executive compensation with 33,111,458 votes for, 1,255,101 against, and 37,082 abstentions.
Approval of the Amended and Restated 2024 Omnibus Incentive Plan received 24,185,333 votes for, 10,177,825 against, and 40,483 abstentions. Stockholders also ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm, with 38,798,633 votes for, 970,082 against, and 65,184 abstentions.
Nu Skin Enterprises reported that Steven K. Hatchett decided to resign as Executive Vice President and Chief Product Officer due to family health circumstances, effective May 8, 2026. He will remain with the company as a strategic product advisor with an annual salary of $147,478.
The filing notes the company’s appreciation for his contributions as Chief Product Officer and confirms that its Chief Financial Officer, Chelsea K. Lantz, signed the report on behalf of the company.
Nu Skin Enterprises reported Q1 2026 revenue of $320.6 million, down 12.0% year over year, with a modest +1.1% foreign-exchange benefit. GAAP diluted EPS was $0.04, or $0.14 excluding inventory write-offs, other charges and impairment, compared with $2.14 or $0.23 on an adjusted basis a year ago when results included a large gain from the Mavely sale.
Customers fell 14% to 669,535, Paid Affiliates declined 8% to 120,850, and Sales Leaders decreased 13% to 26,915. Adjusted operating margin was 3.6% versus 6.4% last year. The company returned $2.9 million via dividends and $5.0 million through share repurchases.
For Q2 2026, Nu Skin guides revenue to $330–$360 million with EPS of $0.15–$0.25. Full-year 2026 revenue is projected at $1.35–$1.50 billion and EPS of $0.70–$1.10, or $0.80–$1.20 excluding specified charges, as it invests behind its Prysm iO wellness platform and emerging-market expansion.
Nu Skin Enterprises entered into a new Second Amended and Restated Credit Agreement on March 27, 2026, establishing a $175 million term loan and a $75 million revolving credit facility, each with a five-year term. The term loan was fully drawn at closing and used to repay all amounts outstanding under the prior credit agreement, effectively refinancing the company’s main bank debt.
The revolving facility includes up to $10 million for swingline loans and up to $10 million for letters of credit. Loans bear interest at Term SOFR plus a spread starting at 1.75% or at a base rate plus a spread starting at 0.75%, with both spreads adjustable based on Nu Skin’s consolidated leverage ratio.
The facilities are guaranteed by certain material domestic subsidiaries and secured by liens on the capital stock of material subsidiaries. Key financial covenants require a consolidated leverage ratio not exceeding 2.25 to 1.00 and an interest coverage ratio of at least 3.00 to 1.00, alongside customary restrictions on additional debt, liens, dividends, acquisitions and asset sales.
Nu Skin Enterprises announced that Executive Vice President and Chief Financial Officer James D. Thomas resigned on March 17, 2026 to pursue an outside opportunity. On March 18, 2026, the board appointed Vice President and Corporate Controller Chelsea K. Lantz as Interim CFO while a search for a permanent CFO, including internal and external candidates, is conducted.
Lantz, age 42, has been with Nu Skin since 2011 in various finance and audit roles and became Corporate Controller in 2023. As Interim CFO she will receive a $300,000 annual salary, a target incentive bonus equal to 35% of salary, and a $25,000 stipend for each quarter she serves in the interim role. The company states there are no family relationships or related-person transactions involving her and expects to enter into a standard indemnification agreement. A press release dated March 20, 2026 announces her appointment and highlights her role in cost-improvement efforts that contributed to a significant year-over-year EPS increase.
Nu Skin Enterprises appointed Chayce D. Clark as Executive Vice President, Chief Operating Officer and Chief Legal Officer. Clark has been the company’s Executive Vice President and General Counsel since 2021 after joining Nu Skin in 2015 and holding several senior legal roles.
In his expanded role, he will oversee revenue performance and end-to-end operational execution, including global sales, product innovation, technology platforms, global programs, brand initiatives and legal services across nearly 50 markets. His base salary is $650,000, with a target annual bonus of 75% of base salary.
Clark’s 2026 annual equity award is valued at $2,362,500, split evenly between time-based RSUs and performance-based RSUs. The RSUs vest 25% in each of 2027–2030, while the PRSUs vest in three tranches based on earnings per share performance in 2026, 2027 and 2028.
Nu Skin Enterprises reported fourth-quarter and full-year 2025 results within guidance, with profitability improving despite lower sales. 2025 revenue was $1.49 billion, down 14.3% from 2024, while diluted EPS rose to $3.18 (or $1.27 excluding the Mavely gain and other charges) from a loss of $(2.95).
Fourth-quarter revenue was $370.3 million, down 16.9%, but EPS improved to $0.29 from $(0.73) as gross margin expanded and restructuring costs fell. Customers declined 10%, and sales leaders fell 19%. For 2026, the company guides revenue to $1.35–$1.50 billion and EPS of $0.80–$1.20, expecting a return to year-over-year revenue growth by year-end driven by its Prysm iO wellness platform and an anticipated India market launch.
Nu Skin Enterprises (NUS) furnished an 8‑K announcing it issued a press release with financial results for the three‑ and nine‑month periods ended September 30, 2025. The release is included as Exhibit 99.1 and the information under Item 2.02 is furnished, not filed, under the Exchange Act. The report lists Class A Common Stock trading on the NYSE and is signed by CFO James D. Thomas.